Tag: Novacyt
Novacyt opens the door of its capital to Biosynex
Subscribe for 1€ Unlimited access to all advice More than 800 stocks listed in Paris and abroad screened. To buy ? To sell ? What course objective? Our experts engage…
Novacyt: Byosinex holds 4.04% of the capital
HC Published on 02/18/2022 at 7:16 p.m. (Boursier.com) —…
Novacyt: Biosynex holds 3% of capital and votes
(CercleFinance.com) – Novacyt announces that Biosynex notified it on February 14, 2022 that as of February 10, 2022, Biosynex’s stake in the Company on the basis of vote and capital…
Novacyt expects Covid test sales to drop ‘around 50%’ this year
Novacyt is in bad shape on the stock market. The shares of the SME, which derives most of its income from the sale of Covid tests, plunged more than 20%…
Novacyt: revenue and Ebitda for the year in line with expectations – 01/25/2022 at 08:46
(AOF) – Novacyt has announced its unaudited business report for the year ending December 31, 2021, along with a strategy update following new chief executive David Allmond’s first 100 days…
Novacyt: the title falls after a point of activity – 01/25/2022 at 09:48
(CercleFinance.com) – Novacyt sank into the red on Tuesday on the Paris Stock Exchange, falling to two-year lows, after a point of activity during which he spoke of the volatile…
Novacyt: the title falls after a point of activity
(CercleFinance.com) – Novacyt sank into the red on Tuesday on the Paris Stock Exchange, falling to two-year lows, after a point of activity during which he mentioned the volatile nature…
Novacyt: 2021 revenue and EBITDA in line with management expectations
(Boursier.com) — Novacyt unveils annual revenue and EBITDA (unaudited) in line with its expectations. The global specialist in clinical diagnostics thus achieved revenues of 95.8 million pounds sterling for the…